Recent performance snapshot Biogen (BIIB) shares closed at US$171.59, with performance mixed across recent periods. The stock shows a 1 day return of about a 1% decline, a 4.4% gain over the past week ...

The past six months have been a windfall for Biogen’s shareholders. The company’s stock price has jumped 41.7%, setting a new ...

Shares of Biogen Inc. slipped 5.04% to $169.31 Wednesday, on what proved to be an all-around grim trading session for the ...

Is Biogen (NASDAQ: BIIB) about to be acquired? One news article published on Wednesday reported that this is a possibility. As a result, the company's shares shot up almost 10% higher on the day. It ...

Biogen Inc. (NASDAQ:BIIB) is one of the best performing pharma stocks in 2025. Biogen Inc. (NASDAQ:BIIB) received several rating updates on January 8. Truist lifted the price target on the stock to ...

Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology ...

Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing, ...

The sale reduced Biogen to 0.03% of reported U.S. equity assets under management as of September 30. Top holdings after the filing: NASDAQ:MSFT: $164.85 million (13.9% of AUM) NASDAQ:AAPL: $122.68 ...

Biogen Q4 adjusted EPS rose 17% to $3.44, beating estimates of $3.35. Revenue hit $2.46 billion, up 2% YOY on constant currency, surpassing $2.40 billion consensus. A new wave of value and momentum ...

Shares of Biogen Inc. BIIB slipped 3.95% to $178.30 Tuesday, on what proved to be an all-around grim trading session for the ...

Biogen Inc. closed 2.40% short of its 52-week high of $190.20, which the company reached on January 9th.